Ocugen COVID-19 vaccine co-development partner, Bharat Biotech shares COVAXIN Phase 3 interim results, demonstrates 81% effectiveness Nasdaq: OCGN
Ocugen COVID-19 vaccine co-development partner, Bharat Biotech shares COVAXIN Phase 3 interim results, demonstrates 81% effectiveness
European Commission grants Ocugen orphan drug designation to candidate gene therapy product, OCU400, for the treatment of retinitis pigmentosa and congenital Leber’s amaurosis
